Outlook Therapeutics, Inc. (OTLK) fundamentals score
Outlook Therapeutics is a biopharmaceutical company that has developed ONS-5010/LYTENAVA TM as the first ophthalmic formulation of bevacizumab approved by the European Commission in the European Union, or EU, and the Medicines and Healthcare products Regulatory Agency, or MHRA, in the United Kingdom, or UK, for use in adults for the treatment of wet age-related macular degeneration, or wet AMD.
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NASDAQ
Overall: 2.8 out of 10, Unhealthy fundamentals
- Growth: 2.3/10
- Profitability: 1.1/10
- Financial health: 1.9/10
- Earnings quality: 8.8/10
- Valuation: 1.5/10
Scores are calculated from Outlook Therapeutics, Inc.’s SEC filings, using the 12 months through 2025-09. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10